Retaspimycin (Hydrochloride)

Retaspimycin Hydrochloride is a potent inhibitor of Hsp90 with EC50s of 119 nM for both Hsp90 and Grp9.

Product Specifications

CAS Number

[857402-63-2]

Product Name Alternative

IPI-504

UNSPSC

12352005

Target

HSP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Retaspimycin-Hydrochloride.html

Purity

96.16

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=C2O)/C(C)=C/C=C\[C@H](OC)[C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](CC2=C(C(O)=C1)NCC=C)C)OC)O)C)OC(N)=O.Cl

Molecular Formula

C31H46ClN3O8

Molecular Weight

624.17

References & Citations

[1]Patterson J, et al. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol. 2008 May;61 (6) :923-32.|[2]Scaltriti M, et al. Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer. Mol Cancer Ther. 2011 May;10 (5) :817-24.|[3]Sydor JR, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A. 2006 Nov 14;103 (46) :17408-13. Epub 2006 Nov 7.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 3

Isoform

HSP90

Citation 01

FASEB J. 2023 Mar;37 (3) :e22832.|J Cell Biochem. 2025 Apr;126 (4) :e70031.|Theranostics. 2019 Aug 12;9 (20) :5769-5783.|Transl Oncol. 2019 Apr 3;12 (6) :801-809.